A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088
Terminated · Phase 1 · NCT06579300
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $157,749
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 72
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-1088 (drug), Placebo for ABBV-1088 (drug), Itraconazole (ITZ) (drug)
- Dates
- Started 2024-09-04; completion 2025-09-03
- Results posted
- Not yet
This study will assess the safety, tolerability, and pharmacokinetics of ABBV-1088 in healthy adult Western, Han-Chinese and Japanese participants. This study will also assess drug-drug interaction between itraconazole and ABBV-1088 in healthy adult Western participants.
From ClinicalTrials.gov, last updated 2025-10-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $157,749 in research payments for this study in 2025 (25 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cenexel Clinical Research Inc $136,799
- $20,950
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.